Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REACT

Financiado

Cerrado

Optimising Radiomics for MRI based personalised cancer treatment

Although cancer survival rates have substantially improved in recent years, cancer is still among the leading causes of morbidity and mortality worldwide. The future of cancer treatment lies in early and better diagnosis and indiv... ver más

16/11/2018

PT THERAGNOSTIC

147K€

Presupuesto del proyecto: 147K€

Líder del proyecto

PT THERAGNOSTIC BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-16

INNOSUP-02-2016: European SME innovation Associate -...

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

PT THERAGNOSTIC

147.21K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PREDICT A new era in personalised medicine Radiomics as decision su... 4M€ Cerrado

CECM Centre for New Methods in Computational Diagnostics and Pers... 400K€ Cerrado

PID2019-105789RB-I00 ROBUST RADIOMIC FEATURES WITH CLINICAL DATA MODELLING FOR CH... 84K€ Cerrado

TED2021-130081B-C21 A COMPREHENSIVE COMPUTER-AIDED DIGANOSIS (CAD) SYSTEM BASED... 193K€ Cerrado

Sano Centre for New Methods in Computational Diagnostics and Pers... 15M€ Cerrado

VPH-PRISM Virtual Physiological Human Personalized Predictive Breast... 5M€ Cerrado

Duración del proyecto: 14 meses Fecha Inicio: 2017-08-17
Fecha Fin: 2018-11-16

Líder del proyecto

PT THERAGNOSTIC BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 147K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Although cancer survival rates have substantially improved in recent years, cancer is still among the leading causes of morbidity and mortality worldwide. The future of cancer treatment lies in early and better diagnosis and individually tailored treatments (‘personalised medicine). ptTheragnostic, a company dedicated to the development of more effective, individualised therapies for cancer patients, is working on a breakthrough solution, Radiomics, that is able to revolutionise personalised cancer treatment. Radiomics is a quantitative image analysis technology that enables patient stratification through the use of routinely acquired biomarkers. Being based on the evolution of hundreds of image-derived features over the course of treatment, Radiomics allows for more sensitive and robust identification of tumour types than currently possible. As MRI is recognised as one of the most promising techniques for the detection of cancer and spread of the disease, ptTheragnostic aims to align Radiomics with MRI. Despite the availability of a multi-disciplinary team at ptTheragnostic, they lack the required expertise and skills to implement Radiomics in the MRI market. Therefore, the goal of this project, REACT, is to hire a skilled associate with expertise in MRI and deep learning to establish this implementation. During the first 12 months, the associate will be responsible for managing the designed innovation track of Radiomics. This includes both technical and business tasks, amongst aligning the Radiomics software with MRI scanners and drafting a marketing strategy for Radiomics. The associate will follow various trainings in the oncology and business field. REACT may therefore open up new career possibilities in both the business and academic (oncology) field. In addition, REACT, will leverage the growth of ptTheragnostic by enabling Radiomics for MRI resulting in a significant increase in revenues (additional 50% in the first year) and increase in FTE (33%).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores